CYTOMEDIX, INC. APPOINTS CARDINAL HEALTH SENIOR EXECUTIVE TO BOARD

Extensive Medical Device Sales and Distribution Background Complements Company's
           Focus on Commercialization of Chronic Wound Care Treatment

LITTLE ROCK, Ark., June 7, 2004 -- Cytomedix, Inc. (OTC BB:CYME) today announced
the appointment of Mark T. McLoughlin to its board of directors, filling a board
vacancy.

      McLoughlin currently serves as vice president and general manager of the
Scientific Products Division of Cardinal Health, Inc. (NYSE:CAH), one of the
world's largest health care manufacturing and distribution companies with sales
in fiscal 2003 of $50.4 billion. In this capacity, he has full general
management responsibility for the distribution, marketing and sales of thousands
of medical devices and reagents that can support more than 90 percent of
laboratory requirements in virtually every clinical laboratory discipline. The
Scientific Products Distribution business of Cardinal Health has served the
clinical laboratory market since 1952. Prior to joining Cardinal, he was vice
president of commercial operations for Norwood Abbey Ltd., an Australian-based
medical technology company. Earlier he was president of North American
operations for Ion Beam Application, Inc., a Belgium-based global medical
technology company. His executive career experience also includes Mallinckrodt,
as well as positions with other healthcare companies.

      "The addition of Mr. McLoughlin to our board represents an ongoing
commitment to attract seasoned professionals with extensive healthcare
experience, both on the board and corporate level. Mark's experience covers the
successful development and implementation of optimum sales and distribution
models for healthcare products, ranging from disposable commodities to
sophisticated and innovative new technologies and capital equipment. We look
forward to his counsel in defining the optimum pathway to rapidly market our
Autologel(TM) technology in the most cost effective manner possible," said Dr.
Kshitij Mohan, chief executive officer of Cytomedix.

      Commenting on his appointment, Mark McLoughlin stated, "I am delighted to
serve on Cytomedix's board and help the company realize the full potential for
its Autologel technology, which offers hope to tens of thousands of diabetic
foot ulcer patients each year who are faced with the possibility of amputations
as a result of this terrible disease -- as well as hope for millions of other
chronic wound patients in the U.S. and worldwide. I look forward to being able
to contribute and help to make this technology available to patients in a rapid
and cost effective manner."

ABOUT CYTOMEDIX

      Cytomedix, Inc. is a biotechnology company specializing in processes and
products derived from autologous platelet releasates. The current product
offering is AutoloGel(TM), an autologous platelet gel composed of multiple
growth factors and fibrin matrix, which is used to treat chronic wounds and
supported by an extensive base of patents. The Company is working with
healthcare providers to offer an advanced therapy at the point-of-care in
multiple settings. It has commenced a well controlled, FDA- approved clinical



trial to seek a specific clinical indication for Autologel(TM) for the treatment
of non-healing diabetic foot ulcers. Additional information is available at:
http://www.cytomedix.com.

Forward Looking Statements

      Statements contained in this press release not relating to historical
facts are forward-looking statements that are intended to fall within the safe
harbor rule for such statements under the Private Securities Litigation Reform
Act of 1995. The information contained in the forward-looking statements is
inherently uncertain, and Cytomedix's actual results may differ materially due
to a number of factors, many of which are beyond Cytomedix's ability to predict
or control, including among others, governmental regulation, acceptance by the
medical community and competition. These forward-looking statements are subject
to known and unknown risks and uncertainties that could cause actual events to
differ from the forward-looking statements. More information about some of these
risks and uncertainties may be found in the reports filed with the Securities
and Exchange Commission by Cytomedix, Inc.

Contact:

For Cytomedix, Inc.
Gary S. Maier
Maier & Company, Inc.
(310) 442-9852

_______________________
Source: Cytomedix, Inc.